Specifications
Immunogen
Recombinant fragment within Human p21 aa 1-164. The exact sequence is proprietary.Database link: P42771
Applications
Application Notes
ICC/IF: 1/100 - 1/1000; WB: 1/500 - 1/3000.
Target
Alternative Names
CDKN1A; cyclin-dependent kinase inhibitor 1A (p21, Cip1); CDKN1; cyclin-dependent kinase inhibitor 1; CAP20; CIP1; P21; p21CIP1; p21Cip1/Waf1; SDI1; WAF1; DNA synthesis inhibitor; CDK-interacting protein 1; CDK-interaction protein 1; wild-type p53-activat
Product Background
Antigen Description
May be the important intermediate by which p53/TP53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex.
Pathway
AKT phosphorylates targets in the cytosol, organism-specific biosystem; AMPK signaling, organism-specific biosystem; Adaptive Immune System, organism-specific biosystem; Adipogenesis, organism-specific biosystem; Alpha6-Beta4 Integrin Signaling Pathway, organism-specific biosystem; Angiopoietin receptor Tie2-mediated signaling, organism-specific biosystem; Bladder cancer, organism-specific biosystem;
Citations
Publication ()
Have you cited DCABH-7892 in a publication?
Let us know and earn a reward for your research.